

“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS

Olga Giouleme

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A multicenter retrospective study of 31 ulcerative colitis patients receiving extended 16-week tofacitinib 10 mg BID induction found that by 24 weeks, 50% achieved steroid-free remission and dose de-escalation was successful in approximately half of those who attempted it.

KEY POINTS

- At 24 weeks, 13 of 26 evaluable patients (50%) achieved steroid-free clinical remission (pMayo <2), and an additional 9 patients with mild disease had discontinued steroids.
- De-escalation from 10 mg BID to 5 mg BID was attempted in 13 patients and was successful in 7 (53.8%), while 6 patients who failed de-escalation regained response after returning to the higher dose.
- Four patients (12.9%) discontinued treatment before week 24 due to inadequate response, and no major adverse events were observed during the study period.
- The study population was heavily pre-treated, with 83.9% having received prior biologics and 80.6% having received systemic corticosteroids.
- This real-world observational study enrolled patients from 10 IBD centers between July 2018 and November 2022 and is ongoing with prospective follow-up.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/6c4a428e-743c-11ee-bec4-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.